Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis |
Salvadori1818.Salvadori C, Merdjan H, Brouard R, Baumelou A, Nicot G, Friès D. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis.Fundam Clin Pharmacol.1990;4:663-71.
|
1990/France |
20 patients with CKD (14 on HD) and 8 patients with normal kidney function |
Blood samples were taken before and at 13 different time points after drug intake for the healthy patients. For patients on HD, dialysis was initiated 2 h after drug administration. Arterial and venous blood samples entering and leaving the dialyzer were simultaneously obtained 1 h after the onset of hemodialysis. |
Not specified |
Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis |
Spigset1919.Spigset O, Hägg S, Stegmayr B, Dahlqvist R. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis.Eur J Clin Pharmacol.2000;56:699-703.
|
2000/Sweden |
4 patients on HD and 8 healthy controls |
Concentrations of citalopram and its metabolites were measured in urine and in serum from the artery leading to the dialyzer and in the dialysate. The drug was given the day after HD. Venous blood samples were collected at 16 different time points after citalopram intake. Urine was collected the first 24 h after drug intake. |
Not specified |
Efficacy and pharmacokinetics of fluvoxamine maleate in patients with mild depression undergoing hemodialysis |
Kamo2020.Kamo T, Horikawa N, Tsuruta Y, Miyasita M, Hatakeyama H, Maebashi Y. Efficacy and pharmacokinetics of fluvoxamine maleate in patients with mild depression undergoing hemodialysis.Psychiatry Clin Neurosci.2004;58:133-7.
|
2004/Japan |
7 patients on HD with comorbid mild depression |
Blood was collected before medication and at 6 different time points after intake of medication for comparison of the plasma concentrations of fluvoxamine. |
Mild depression according to ICD-10 and HDRS-17 (score of 14 or higher) |
Hemodialyzability of sertraline |
Schwenk2121.Schwenk MH, Verga MA, Wagner JD. Hemodialyzability of sertraline.Clin Nephrol.1995;44:121-4.
|
1995/USA |
2 patients on HD |
The drug was administered after hemodialysis. During the next hemodialysis session, simultaneous pre- and post-dialyzer blood samples were obtained at the start of dialysis and hourly throughout until completion. All spent dialysate was collected hourly, quantified, and an aliquot retained. Additional blood samples were obtained approximately 20 h after dialysis and prior to the next treatment. |
Not specified |
Response to nefazodone in a depressed patient with end-stage renal disease |
Seabolt2222.Seabolt JL, De Leon OA. Response to nefazodone in a depressed patient with end-stage renal disease.Gen Hosp Psychiatry.2001;23:45-6.
|
2001/USA |
1 patient on HD |
Pre- and post-dialysis nefazodone serum concentrations were measured. |
HDRS |
The pharmacokinetics of nortriptyline in patients with chronic renal failure |
Dawlilng2323.Dawlilng S, Lynn K, Rosser R, Braithwaite R. The pharmacokinetics of nortriptyline in patients with chronic renal failure.Br J Clin Pharmacol.1981;12:39-45.
|
1981/United Kingdom |
20 patients with CKD (8 on HD) |
Patients received the drug immediately following dialysis. Plasma nortriptyline half-life and total hepatic intrinsic clearance were calculated. |
Not specified |
Therapeutic drug monitoring of antidepressants in haemodialysis patients |
Unterecker2424.Unterecker S, Müller P, Jacob C, Riederer P, Pfuhlmann B. Therapeutic drug monitoring of antidepressants in haemodialysis patients.Clin Drug Investig.2012;32:539-45.
|
2012/Germany |
32 patients on HD |
The serum concentration of the drug was measured in two blood samples. The first was obtained immediately after puncture of the dialysis port, and the second just before disconnecting the patient from the dialysis machine. |
Not specified |
Mirtazapine oral single dose kinetics in patients with different degrees of renal failure |
Bengtsson2525.Bengtsson F, Hoglund P, Timmer C, Hegbrant J. Mirtazapine oral single dose kinetics in patients with different degrees of renal failure.Hum Psychopharmacol.1998;13:357-65.
|
1998/United Kingdom |
40 patients (2 on HD) |
Blood samples were taken at 25 different time points after ingestion of the drug. |
Not specified |
No influence of dialysis on mirtazapine – a case report |
Schlotterbeck2626.Schlotterbeck PM, Vehren T, Milenovic S, Hiemke C, Kircher T, Leube D. No influence of dialysis on mirtazapine – a case report.Pharmacopsychiatry.2008;41:259-60.
|
2008/Germany |
1 patient on HD |
Plasma was obtained before a dialysis session and once again four hours later, the extracted dialysate for the concentration was also analyzed. |
Not specified |
Fluoxetine in depressed patients on dialysis |
Blumenfield2727.Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr, Dubey AK, et al. Fluoxetine in depressed patients on dialysis.Int J Psychiatry Med.1997;27:71-80.
|
1997/USA |
7 healthy controls and 6 patients on HD |
Blood samples were obtained to measure the plasma concentration of the drug in 6 different moments. |
HDRS (total score of at least 16 on the first seventeen items) |
Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function |
Levy2828.Levy NB, Blumenfield M, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function.Gen Hosp Psychiatry.1996;18:8-13.
|
1996/USA |
9 healthy patients and 7 patients on HD |
Plasma concentrations of the drug were measured on 9 different moments. |
Clinical interview and a score of at least 16 on first HDRS-17 |